A health care winner no matter what

Generic drug makers like Teva see upside in health care debate

By Kim Peterson Oct 13, 2009 3:13PM
Jim JubakNo matter what health care reform bill emerges from Congress this year -- or if there's no bill at all -- the pressure to get costs out of the health care system is just going to get more intense. (For the reasons why, see my October 13th post)

In that effort, requiring that health plans replace proprietary drugs with generics is an easy way to cut costs (or to look like you're cutting costs).

So, generic drug makers win once because any legislation will expand the number of insured able to afford drugs, and twice, because economics will continue to move patients, doctors, and health care bill payers to generics.

No wonder Teva Pharmaceutical Industries (TEVA) is guiding Wall Street to 30% earnings growth in 2010.

Teva is the world's largest generic drug maker. In generic drugs, bigger is better, since it allows a company to spread development, manufacturing, and marketing costs over a larger customer base.

So, for example, the company's 2008 acquisitions of Barr, the number-four generic drug company, and Bentley Pharmaceuticals added market share in Europe, which in 2008 accounted for just 28% of the company's sales.

In the longer range -- say, five years out or so -- Teva looks to be one of the best positioned generic companies to tackle the new market for biogenerics. These drugs are generic versions of the drugs developed by biotech companies.

So far, the size of this market has been extremely limited by the lack of an appropriate regulatory framework for ruling on what constitutes a safe generic version of a biotech drug. Legislation is likely this year or next, and Teva is one of a small number of generic companies with the financial resources to tackle this new market.

The company estimates that it will cost about $100 million to $150 million per drug to reverse-engineer a similar drug from a biotechnology company, versus about $10 million to $15 million to reverse-engineer a conventionally small molecule drug.

As of October 13, 2009, I'm adding Teva Pharmaceutical Industries to Jubak's Picks with a target price of $61 a share by October 2010. That values Teva at about 14x my estimate of 2010 earnings of $4.35 a share.

As of October 13th, the stock traded above $51 -- 14.25 times Standard & Poor's estimate of 2009 earnings.

At the time of this writing, Jim Jubak did not own or control shares of any company mentioned in this post.



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123 rated 1
262 rated 2
480 rated 3
651 rated 4
649 rated 5
629 rated 6
616 rated 7
496 rated 8
346 rated 9
111 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.